The  frequency and clinical  course of retinopathy of prematurity in modern developmental care  conditions as evidenced by the Moscow region perinatal center

Катаргина, Л А; Trusova, S. A.; Shevernaya, O. A.; Osipova, N A; Panova, A. Yu.

doi:10.21516/2072-0076-2020-13-3-15-20

Rossijskij oftalʹmologičeskij žurnal

2020

DOI: 10.21516/2072-0076-2020-13-3-15-20

|View full text |Cite

The frequency and clinical course of retinopathy of prematurity in modern developmental care conditions as evidenced by the Moscow region perinatal center

Л А Катаргина

S. A. Trusova²,

O. A. Shevernaya³

et al.

Abstract: to determine the incidence and clinical course of retinopathy of prematurity (ROP) in modern developmental care conditions as based by the data of a level III perinatal center. Material and methods. A retrospective study of 920 premature infants of the ROP at-risk cohort managed by the Neonatology department of Moscow Regional Perinatal Center over the 2-year period of 2017-2018 was performed. The frequency and clinical course of retinopathy of prematurity in modern developmental care conditions as evidenced b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Reactivation of retinopathy of prematurity after ranibizumab treatment

Revta,

Usynina

2024

Russian Pediatric Ophthalmology

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is one of the most common causes of visual disability in children born prematurely. Intravitreal injection of angiogenesis inhibitors (antivascular endothelial growth factor [VEGF] therapy) is considered one of the conservative methods of treating ROP. Aim: This study aimed to present a clinical case of ROP reactivation after intravitreal injection of the antiVEGF drug ranibizumab (Lucentis). MATERIAL AND METHODS: The course of retinopathy in a premature infant with extremely low birth weight was studied. RESULTS: A patient diagnosed with ROP, a posterior aggressive form of both eyes, received intravitreal injections of an angiogenesis inhibitor at 36 postconceptional weeks. During subsequent follow-up, disease progression was noted, which necessitated repeated ranibizumab administrations to both eyes. Over time, tractional retinal detachment developed in the right eye, and the disease progressed more slowly in the left eye. At the age of 1 year, ROP rapidly progressed to stage 4B in the left eye. Lens vitrectomy was performed sequentially on the right and then on the left eye. At the age of 1.5 years, the patient had coarse preretinal adhesions in the posterior pole of both eyes and had no spatial vision, whereas light perception was preserved. CONCLUSION: Intravitreal ranibizumab administration for posteriorly aggressive ROP does not exclude its reactivation both early and late after administrations. Further improvement in treatment methods for ROP is necessary.

show abstract

Reactivation of retinopathy of prematurity after ranibizumab treatment

Revta,

Usynina

2024

Russian Pediatric Ophthalmology

View full text Add to dashboard Cite

show abstract

Role of studying the pathogenesis of retinopathy of prematurity in optimizing disease screening

Катаргина

Чеснокова

Balatskàyà

et al. 2021

Russian Pediatric Ophthalmology

View full text Add to dashboard Cite

Background: The efficiency of treatment and prevention of retinopathy of prematurity (ROP) has improved. In addition, the development of a disease screening system to reduce the incidence of disability resulting from this pathology is important. Aim: This study aimed to determine new laboratory criteria for screening and predicting the ROP course through in-depth investigation of the molecules participating in the pathogenesis of ROP. Material and methods: A comprehensive clinical and experimental study was performed to assess the local and systemic levels of 49 cytokines with various biological effects, four monoamines, and angiotensin-II (AT-II) at different stages of the pathological process. In the clinical analysis, 165 preterm infants at risk of ROP development were examined. For the experimental part, the disease course of 145 Wistar infant rats in the developed model of experimental ROP was analyzed. Results: Among cytokines, the seven most promising potential laboratory markers of ROP development and adverse course were as follows: MCP1 95 pg/mL, IGF-II 140 pg/mL, TGFbeta1 18000 pg/mL, and IGF-I 24 pg/mL in the blood serum of preterm infants before the first signs of ROP and VEGF-A 108 pg/mL, TGF-beta2 100 pg/mL, and PDGF-BB 1800 pg/mL at ROP manifestation. Among monoamines, serotonin (17.0 pg/mL) and L-DOPA indicated their prognostic value in the clinical and experimental settings. Moreover, a possible prognostic role of AT-II was found. Conclusion: In this study, methods to improve the ROP screening system are outlined, but further work is necessary to assess the possibility of implementing the results in clinical practice

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The frequency and clinical course of retinopathy of prematurity in modern developmental care conditions as evidenced by the Moscow region perinatal center

Cited by 2 publications

References 3 publications

Reactivation of retinopathy of prematurity after ranibizumab treatment

Reactivation of retinopathy of prematurity after ranibizumab treatment

Role of studying the pathogenesis of retinopathy of prematurity in optimizing disease screening

Contact Info

Product

Resources

About